Matches in SemOpenAlex for { <https://semopenalex.org/work/W2027016850> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2027016850 endingPage "S423" @default.
- W2027016850 startingPage "S423" @default.
- W2027016850 abstract "P1043 REAL-LIFE PERSISTENCE AND ADHERENCE IN ETV TREATED CHRONIC HEPATITIS B PATIENTS: RESULTS OF A GERMAN PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY J. Petersen, T. Wilke, S. Mauss, R. Heyne, C. Herold, M. Wiese, K. Boeker, T. Pichl, D. Hueppe. ifi – Institut fur Interdisziplinare Medizin, Hamburg, IPAM Wismar, Wismar, Medizinisches Versorgungszentrum, Duesseldorf, Leberzentrum Checkpoint, Berlin, Internisten am Ring, Nuernberg, Gesellschaft fur Klinische Studien, Leipzig, Leberpraxis Hannover, Hannover, BristolMyers Squibb GmbH & Co. KGaA, Munich, Gastroenterologische Gemeinschaftspraxis Herne, Herne, Germany E-mail: petersen@ifi-medizin.de Background and Aims: Entecavir (ETV) is a very effective and safe treatment option in chronic hepatitis B (CHB) patients. However, some patients show only a partial virologic response. The most reasonable explanation is non-persistence/non-adherence. Persistence and adherence measurement is underrepresented in clinical trials. Therefore, the extent of non-persistence (NP), nonadherence (NA) and clinical outcomes of any NP/NA were measured in ETV-treated patients in a real-life study. Methods: In a prospective observational multicenter study, persistence and adherence were measured based on documented ETV prescriptions within a 12 month period. A patient was defined as NP if he missed all treatment doses in >30 subsequent days. Adherence was measured based on medication possession ratio (MPR) between first and last documented prescription (NA if MPR 30 subsequent days (NP group), 30% of patients in the NP group (n =9) and none of the persistent patients were classified as non-adherent. Mean MPR for all patients was 95.3%. 84.4% of persistent/adherent patients and 63.0% of patients in the NP group reached undetectable HBV-DNA levels (p = 0.022). So far no significantly correlating factors for NP/NA could be detected." @default.
- W2027016850 created "2016-06-24" @default.
- W2027016850 creator A5012564454 @default.
- W2027016850 creator A5012738095 @default.
- W2027016850 creator A5026686430 @default.
- W2027016850 creator A5029582159 @default.
- W2027016850 creator A5041124674 @default.
- W2027016850 creator A5059506644 @default.
- W2027016850 creator A5068787709 @default.
- W2027016850 creator A5073918424 @default.
- W2027016850 creator A5091148785 @default.
- W2027016850 date "2014-04-01" @default.
- W2027016850 modified "2023-09-26" @default.
- W2027016850 title "P1043 REAL-LIFE PERSISTENCE AND ADHERENCE IN ETV TREATED CHRONIC HEPATITIS B PATIENTS: RESULTS OF A GERMAN PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY" @default.
- W2027016850 doi "https://doi.org/10.1016/s0168-8278(14)61203-4" @default.
- W2027016850 hasPublicationYear "2014" @default.
- W2027016850 type Work @default.
- W2027016850 sameAs 2027016850 @default.
- W2027016850 citedByCount "0" @default.
- W2027016850 crossrefType "journal-article" @default.
- W2027016850 hasAuthorship W2027016850A5012564454 @default.
- W2027016850 hasAuthorship W2027016850A5012738095 @default.
- W2027016850 hasAuthorship W2027016850A5026686430 @default.
- W2027016850 hasAuthorship W2027016850A5029582159 @default.
- W2027016850 hasAuthorship W2027016850A5041124674 @default.
- W2027016850 hasAuthorship W2027016850A5059506644 @default.
- W2027016850 hasAuthorship W2027016850A5068787709 @default.
- W2027016850 hasAuthorship W2027016850A5073918424 @default.
- W2027016850 hasAuthorship W2027016850A5091148785 @default.
- W2027016850 hasConcept C126322002 @default.
- W2027016850 hasConcept C127413603 @default.
- W2027016850 hasConcept C154775046 @default.
- W2027016850 hasConcept C159047783 @default.
- W2027016850 hasConcept C166957645 @default.
- W2027016850 hasConcept C168563851 @default.
- W2027016850 hasConcept C187320778 @default.
- W2027016850 hasConcept C23131810 @default.
- W2027016850 hasConcept C2522874641 @default.
- W2027016850 hasConcept C2781009140 @default.
- W2027016850 hasConcept C2992435398 @default.
- W2027016850 hasConcept C3020491458 @default.
- W2027016850 hasConcept C71924100 @default.
- W2027016850 hasConcept C95457728 @default.
- W2027016850 hasConceptScore W2027016850C126322002 @default.
- W2027016850 hasConceptScore W2027016850C127413603 @default.
- W2027016850 hasConceptScore W2027016850C154775046 @default.
- W2027016850 hasConceptScore W2027016850C159047783 @default.
- W2027016850 hasConceptScore W2027016850C166957645 @default.
- W2027016850 hasConceptScore W2027016850C168563851 @default.
- W2027016850 hasConceptScore W2027016850C187320778 @default.
- W2027016850 hasConceptScore W2027016850C23131810 @default.
- W2027016850 hasConceptScore W2027016850C2522874641 @default.
- W2027016850 hasConceptScore W2027016850C2781009140 @default.
- W2027016850 hasConceptScore W2027016850C2992435398 @default.
- W2027016850 hasConceptScore W2027016850C3020491458 @default.
- W2027016850 hasConceptScore W2027016850C71924100 @default.
- W2027016850 hasConceptScore W2027016850C95457728 @default.
- W2027016850 hasIssue "1" @default.
- W2027016850 hasLocation W20270168501 @default.
- W2027016850 hasOpenAccess W2027016850 @default.
- W2027016850 hasPrimaryLocation W20270168501 @default.
- W2027016850 hasRelatedWork W1977295299 @default.
- W2027016850 hasRelatedWork W2312748458 @default.
- W2027016850 hasRelatedWork W2313076522 @default.
- W2027016850 hasRelatedWork W2521565175 @default.
- W2027016850 hasRelatedWork W2765980456 @default.
- W2027016850 hasRelatedWork W2976382042 @default.
- W2027016850 hasRelatedWork W2981703979 @default.
- W2027016850 hasRelatedWork W2985895894 @default.
- W2027016850 hasRelatedWork W4300415465 @default.
- W2027016850 hasRelatedWork W2464797648 @default.
- W2027016850 hasVolume "60" @default.
- W2027016850 isParatext "false" @default.
- W2027016850 isRetracted "false" @default.
- W2027016850 magId "2027016850" @default.
- W2027016850 workType "article" @default.